CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 31 enrolled
Drug / intervention
FE 202158drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01612676
NCT01612676Phase 2Completed
CompareCT.gov

An Open Label Feasibility Trial Investigating FE 202158 as Potential Primary Vasopressor Treatment in Patients With Vasodilatory Hypotension in Early Septic Shock.

Ferring Pharmaceuticals·interventional·Posted Jun 6, 2012·Updated Mar 23, 2017

In Brief

A Phase 2 clinical trial evaluating FE 202158 for Septic Shock. Completed, enrolled 31 participants across 4 sites in 2 countries.

Detailed Summary

The purpose of this trial is to investigate the potential of FE 202158 as a treatment which can stabilize blood pressure for treatment of patients in early septic shock.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSeptic Shock
CountriesBelgium, Denmark
Collaborators--

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJun 6, 2012
Enrollment StartJun 1, 2012
Primary CompletionNov 1, 2013
TodayJul 3, 2026
Enrollment to primary: 1.4 yearsPosted 14.1 years ago

Interventions

FE 202158drug